Stock Analiz

10x Genomics, Inc. (TXG) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

10x Genomics’s revenue went from $71M in fiscal 2017 to $643M in fiscal 2025, growth of about 31.7% a year.

Net income in fiscal 2025 was -$44M, a net margin of -6.8%; the best year in this period was 2017 with -$19M.

Over the twelve months to September 30, 2026, revenue was $619M and net income -$67M.

Free cash flow was $130M in fiscal 2025 and positive in 1 of the 9 years shown.

The diluted share count rose 977% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $71M172018: $146M182019: $246M192020: $299M202021: $490M212022: $516M222023: $619M232024: $611M242025: $643M25$643M
Net income
2017: -$19M172018: -$112M182019: -$31M192020: -$543M202021: -$58M212022: -$166M222023: -$255M232024: -$183M242025: -$44M25-$44M
Free cash flow
2017: -$14M172018: -$83M182019: -$8M192020: -$255M202021: -$123M212022: -$165M222023: -$64M232024: -$6M242025: $130M25$130M
EPS (diluted)
2017: $-1.62172018: $-8.40182019: $-0.80192020: $-5.37202021: $-0.53212022: $-1.46222023: $-2.18232024: $-1.52242025: $-0.3525$-0.35

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$619M$643M$611M$619M$516M$490M$299M$246M$146M$71M
Gross profit$445M$444M$414M$409M$396M$416M$240M$185M$118M$61M
Operating income-$72M-$61M-$195M-$265M-$168M-$52M-$534M-$31M-$111M-$18M
Net income-$67M-$44M-$183M-$255M-$166M-$58M-$543M-$31M-$112M-$19M
EPS (diluted)$-0.52$-0.35$-1.52$-2.18$-1.46$-0.53$-5.37$-0.80$-8.40$-1.62
R&D$223M$239M$265M$270M$266M$212M$123M$83M$48M$32M
Revenue growth—+5.2%−1.3%+19.8%+5.3%+64.1%+21.5%+68.1%+105.8%—

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow$100M$136M$7M-$15M-$34M-$21M-$218M$35M-$76M-$11M
Capital spending-$6M-$6M-$12M-$49M-$132M-$101M-$37M-$43M-$6M-$4M
Free cash flow$94M$130M-$6M-$64M-$165M-$123M-$255M-$8M-$83M-$14M
Dividends paid—$0$0$0$0$0$0$0$0$0
Buybacks—————————$80000
Stock-based pay$97M$109M$141M$167M$137M$96M$49M$13M$3M$2M

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$523M$393M$389M$430M$587M$664M$424M$65M$48M
Debt—$84M$83M$95M$95M$82M$63M$84M$30M—
Equity—$796M$710M$741M$806M$818M$739M$420M-$220M-$113M
Total assets—$1.0B$919M$965M$1.0B$1.0B$929M$606M$124M—
Shares (diluted)131M125M120M117M114M110M101M39M13M12M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin71.9%69.0%67.9%66.1%76.7%84.9%80.4%75.2%80.4%85.1%
Operating margin-11.7%-9.5%-31.9%-42.9%-32.5%-10.7%-178.7%-12.4%-75.7%-25.9%
Net margin-10.8%-6.8%-29.9%-41.2%-32.1%-11.9%-181.6%-12.7%-76.9%-26.4%
FCF margin15.2%20.2%-0.9%-10.3%-32.0%-25.0%-85.2%-3.3%-56.5%-20.3%
ROIC—-5.5%-19.4%-25.1%-14.7%-4.6%-52.6%-4.8%——
ROE—-5.5%-25.7%-34.4%-20.6%-7.1%-73.4%-7.4%51.1%16.7%

Frequently asked questions

What is 10x Genomics’s annual revenue?

$643M in fiscal 2025 and $619M over the twelve months to September 30, 2026.

How much profit does 10x Genomics make?

Net income was -$44M in fiscal 2025 (net margin -6.8%).

Is 10x Genomics’s revenue growing?

Yes: revenue rose 5.2% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.